Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
54
PCVX Quote, Financials, Valuation and Earnings
Last price:
$46.51
Seasonality move
:
4.77%
Day range:
$45.11 - $46.79
52-week range:
$27.66 - $94.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.10x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
-48.38%
Market cap:
$6.1B
Revenue:
--
EPS (TTM):
-$4.92
Analysts' Opinion
-
Consensus RatingVaxcyte, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $92.00, Vaxcyte, Inc. has an estimated upside of 97.94% from its current price of $46.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing 100% downside risk from its current price of $46.48.
Fair Value
-
According to the consensus of 8 analysts, Vaxcyte, Inc. has 97.94% upside to fair value with a price target of $92.00 per share.
PCVX vs. S&P 500
-
Over the past 5 trading days, Vaxcyte, Inc. has underperformed the S&P 500 by -6.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vaxcyte, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vaxcyte, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vaxcyte, Inc. reported revenues of --.
Earnings Growth
-
Vaxcyte, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Vaxcyte, Inc. reported earnings per share of -$1.56.
Enterprise value:
4.5B
EV / Invested capital:
1.50x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-1.81x
EV / Free cash flow:
-7.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$19.8M
Return On Assets:
-19.39%
Net Income Margin (TTM):
--
Return On Equity:
-20.68%
Return On Invested Capital:
-20.23%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$9.5M | -$14M | -$19.8M | -$4.5M | -$5.2M | |
| Operating Income | -$334.9M | -$529.1M | -$811.6M | -$139.9M | -$242.4M | |
| EBITDA | -$325.4M | -$515M | -$791.7M | -$135.4M | -$237.2M | |
| Diluted EPS | -$3.34 | -$4.68 | -$4.92 | -$0.83 | -$1.56 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $302.9M | $369.8M | $1.3B | $2.2B | $1.8B | |
| Total Assets | $354.1M | $412.1M | $1.5B | $3.6B | $3.2B | |
| Current Liabilities | $47.5M | $39.3M | $85.6M | $123.8M | $200M | |
| Total Liabilities | $48.1M | $52.8M | $93.3M | $142.1M | $278.7M | |
| Total Equity | $306M | $359.3M | $1.4B | $3.4B | $2.9B | |
| Total Debt | $1.2M | $13.4M | $7.8M | $18.3M | $78.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$233.2M | -$470M | -$542.1M | -$60.7M | -$143.3M | |
| Cash From Investing | -$795.3M | -$1.5B | -$234.9M | -$917M | $121.2M | |
| Cash From Financing | $1.3B | $2.4B | $4.5M | $1.5B | -$3.7M | |
| Free Cash Flow | -$245.2M | -$616.2M | -$620.7M | -$98.8M | -$155.4M | |
PCVX
Sector
Market Cap
$6.1B
$28.5M
Price % of 52-Week High
49.13%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.87%
-1.33%
1-Year Price Total Return
-48.38%
-20.32%
Beta (5-Year)
1.279
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$47.50
200-day SMA
Buy
Level
$40.99
Bollinger Bands (100)
Buy
Level
31.96 - 44.6
Chaikin Money Flow
Sell
Level
-7.3M
20-day SMA
Sell
Level
$47.09
Relative Strength Index (RSI14)
Buy
Level
51.68
ADX Line
Buy
Level
29.7
Williams %R
Neutral
Level
-58.3975
50-day SMA
Buy
Level
$43.88
MACD (12, 26)
Buy
Level
1.01
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
43M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (26.4438)
Buy
CA Score
(Annual)
Level (0.4235)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.8416)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Stock Forecast FAQ
In the current month, PCVX has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PCVX average analyst price target in the past 3 months is $92.00.
-
Where Will Vaxcyte, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vaxcyte, Inc. share price will rise to $92.00 per share over the next 12 months.
-
What Do Analysts Say About Vaxcyte, Inc.?
Analysts are divided on their view about Vaxcyte, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vaxcyte, Inc. is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is Vaxcyte, Inc.'s Price Target?
The price target for Vaxcyte, Inc. over the next 1-year time period is forecast to be $92.00 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PCVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vaxcyte, Inc. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PCVX?
You can purchase shares of Vaxcyte, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vaxcyte, Inc. shares.
-
What Is The Vaxcyte, Inc. Share Price Today?
Vaxcyte, Inc. was last trading at $46.51 per share. This represents the most recent stock quote for Vaxcyte, Inc.. Yesterday, Vaxcyte, Inc. closed at $46.48 per share.
-
How To Buy Vaxcyte, Inc. Stock Online?
In order to purchase Vaxcyte, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PCVX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PCVX
Sector
P/E ratio
--
23.75x
PEG ratio
-1.81x
-0.01x
P/B ratio
2.10x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
PCVX
Sector
Revenue growth
--
4.85%
Earnings growth
-87.44%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.24
-$0.20
Profitability
PCVX
Sector
Profitability FY 2024
-$15.8M
$3.6M
Return on invested capital
-20.23%
-30.98%
Return on assets
-19.39%
-27.62%
Return on equity
-20.68%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
PCVX
Sector
Total cash
$1.7B
$27.2M
Short term investments
$1.4B
$25.7M
Total assets
$3.5B
$79.7M
Long term debt
$78.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
